Zydus -Saroglitazar -FDA fast track designation for PBC

Zydus -Saroglitazar -FDA fast track designation for PBC

Zydus -Saroglitazar -FDA fast track designation for PBC

Drug firm Zydus Cadila on Wednesday said it has received Fast Track Designation from the US health regulator for its investigational drug candidate Saroglitazar Mg, indicated for the treatment of a liver disease – primary biliary cholangitis (PBC).

shares